• Publications
  • Influence
Control of cell cycle progression by c-Jun is p53 dependent.
The c-jun proto-oncogene encodes a component of the mitogen-inducible immediate-early transcription factor AP-1 and has been implicated as a positive regulator of cell proliferation and G1-to-S-phaseExpand
  • 540
  • 16
The Mammalian UV Response c-Jun Induction Is Required for Exit from p53-Imposed Growth Arrest
The mammalian UV response results in rapid and dramatic induction of c-jun. Induction of a protooncogene, normally involved in mitogenic responses, by a genotoxic agent that causes growth arrestExpand
  • 295
  • 11
Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator
Because of the limitations and liabilities of current testosterone therapies, non-steroidal tissue-selective androgen receptor modulators may provide a clinically meaningful advance in therapy. UsingExpand
  • 24
  • 2
392 A SELECTIVE ESTROGEN RECEPTOR BETA AGONIST MODULATES NEUROPATHIC AND INFLAMMATORY PAIN STATES
Background and aims. The effects of estrogens on pain perception remain quite controversial. Depending on the animal models, both beneficial and detrimental effects of non-selective estrogens haveExpand
  • 1
Transforming growth factor beta 1-mediated growth inhibition in chick embryo fibroblasts: reversion by virally-expressed nuclear oncogenes.
Transforming growth factor beta 1 (TGF-beta 1) inhibits growth of primary cultures of chick embryo fibroblasts by affecting G1 and strongly increasing the generation time. This inhibition is reversedExpand
  • 4
Funcational assay platform to identify novel inhibitors of receptor tyrosine kinases
3144 Background: ACADIA has developed a functional assay to detect Receptor Tyrosine Kinase (RTK) activity, using its unique proprietary platform technology Receptor and Selection AmplificationExpand
Identification of histamine H3 receptor antagonists
In vitro and in vivo profile of a novel tissue selective, orally bioavailable non-steroidal androgen receptor modulator (ACP-105)
Clinical experience with testosterone suggests a wide range of indications for selective androgen receptors modulators (SARMs), including hypogonadism, osteoporosis, CNS indications and muscle wast...